天然产物研究与开发 ›› 2026, Vol. 38 ›› Issue (2): 326-338.doi: 10.16333/j.1001-6880.2026.2.010 cstr: 32307.14.1001-6880.2026.2.010

• 开发研究 • 上一篇    下一篇

异鼠李素通过抑制凝集素蛋白调控鼻咽癌细胞的机制研究

李秋菊1,2,李汝婷1,杜玉珊1,马丽娟1*   

  1. 1湖南师范大学附属第一医院(湖南省人民医院),长沙 410005;2贵阳市妇幼保健院,贵阳 550000
  • 出版日期:2026-02-26 发布日期:2026-02-25
  • 基金资助:
    湖南省教育厅重点项目(21A0040);湖南省人民医院博士基金暨2022年国自培育项目(BSJJ202115)

Mechanism of isorhamnetin in regulating nasopharyngeal carcinoma cells by inhibiting clusterin

LI Qiu-ju1,2,LI Ru-ting1,DU Yu-shan1,MA Li-juan1*   

  1. 1The First Affiliated Hospital of Hunan Normal University (Hunan Provincial People′s Hospital),Changsha 410005,China; 2Guiyang Maternal and Child Health Hospital,Guiyang 550000,China
  • Online:2026-02-26 Published:2026-02-25

摘要:

探索异鼠李素(isorhamnetin,IH)对鼻咽癌(nasopharyngeal carcinoma,NPC)细胞的作用及机制。使用不同浓度IH处理NPC细胞系C666-1,研究其对C666-1细胞增殖、迁移、侵袭、凋亡与细胞周期的影响。基于网络药理学及分子对接预测IH的作用靶点及通路,在DisGeNET、GeneCards、OMIM数据库获取NPC疾病靶点,在SwissTargetPrediction数据库获取IH作用靶点,利用Venny、Cytoscape 3.10.1、String和Metascape数据库分析IH作用于NPC的核心靶点及通路,通过分子对接验证IH与核心靶点之间的结合能力,随后通过转录组测序分析IH处理后C666-1的差异表达基因及信号通路,最后通过Western blot法检测作用靶点及信号通路的蛋白表达。结果显示,IH可以呈浓度依赖性抑制C666-1的增殖、迁移、侵袭能力,促进细胞凋亡,阻滞细胞周期在G1期。网络药理学预测其作用核心靶点是凝集素蛋白(clusterin,CLU)、蛋白激酶B(protein kinase B,AKT)、表皮生长因子受体(epidermal growth factor receptor,EGFR)、基质金属蛋白酶9(matrix metalloproteinase 9,MMP9),分子对接显示IH与CLU的结合最稳定(结合能-9.1 kcal/mol),KEGG分析筛选出的通路主要涉及磷脂酰肌醇3-激酶(phosphoinositide 3-kinase,PI3K)/AKT、EGFR酪氨酸激酶抑制剂耐药、癌症通路等,转录组测序结果显示前20个差异通路中差异性最显著的是PI3K/AKT,Western blot显示IH处理后CLU、磷酸化磷脂酰肌醇3-激酶(p-PI3K)以及磷酸化蛋白激酶B(p-AKT)表达量均呈剂量依赖性下降。综上,IH可以通过抑制CLU、PI3K/AKT通路抑制NPC细胞。

关键词: 异鼠李素, 鼻咽癌, 网络药理学, PI3K/AKT信号通路, 聚集素蛋白

Abstract:

This study aimed to explore the effects and mechanisms of isorhamnetin (IH) on nasopharyngeal carcinoma (NPC) cells.The NPC cell line C666-1 was treated with different concentrations of IH to investigate its effects on cell proliferation,migration,invasion,apoptosis,and cell cycle.Network pharmacology and molecular docking approaches were adopted to predict the action targets and signaling pathways of IH.The disease-related targets of NPC were obtained from the DisGeNET,GeneCards,and OMIM databases,and the potential action targets of IH were obtained from the SwissTargetPrediction database.To identify the core targets and pathways of IH in acting on NPC,multiple bioinformatics tools and databases,including Venny,Cytoscape 3.10.1,String,and Metascape,were employed.Molecular docking was further conducted to validate the binding affinity between IH and the core targets.Subsequently,transcriptome sequencing was performed to analyze the differentially expressed genes and perturbed signaling pathways in C666-1 cells following IH treatment.Finally,the protein expression levels of the action targets and key components of the signaling pathways were detected by Western blot.The results showed that IH could inhibit the proliferation,migration,and invasion abilities of C666-1 cells in a concentration-dependent manner.Also IH significantly promoted apoptosis and arrested the cell cycle at the G1 phase.Network pharmacology analysis predicted that clusterin (CLU),protein kinase B (AKT),epidermal growth factor receptor (EGFR),and matrix metalloproteinase 9 (MMP9) were the core action targets of IH.Molecular docking results indicated that IH exhibited the most stable binding to CLU( binding energy:-9.1 kcal/mol ).KEGG pathway enrichment analysis revealed that the signaling pathways significantly affected by IH mainly included the phosphoinositide 3-kinase (PI3K)/AKT pathway,EGFR tyrosine kinase inhibitor resistance pathway,and several cancer-related pathways.Results of transcriptome sequencing demonstrated that the PI3K/AKT pathway exhibited the most significant changes among the top 20 differentially-regulated pathways.Western blot analysis confirmed that the protein expression levels of CLU,phosphorylated PI3K (p-PI3K),and phosphorylated AKT (p-AKT) decreased in a dose-dependent manner after IH treatment.In conclusion,this study provides evidence that IH exerts inhibitory effects on NPC cells by suppressing the CLU and PI3K/AKT signaling pathways.

Key words: nasopharyngeal carcinoma, isorhamnetin, network pharmacology, PI3K/AKT pathway, clusterin

中图分类号:  R766.3